CA2183329A1 - Procede de traitement et d'inhibition des ulceres gastriques et duodenaux - Google Patents

Procede de traitement et d'inhibition des ulceres gastriques et duodenaux

Info

Publication number
CA2183329A1
CA2183329A1 CA002183329A CA2183329A CA2183329A1 CA 2183329 A1 CA2183329 A1 CA 2183329A1 CA 002183329 A CA002183329 A CA 002183329A CA 2183329 A CA2183329 A CA 2183329A CA 2183329 A1 CA2183329 A1 CA 2183329A1
Authority
CA
Canada
Prior art keywords
galactose
oligosaccharide
group
stomach
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002183329A
Other languages
English (en)
Inventor
David A. Zopf
Paul M. Simon
Stephen Roth
Edward J. Mcguire
Dennis H. Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neose Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2183329A1 publication Critical patent/CA2183329A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé traitant et/ou inhibant les ulcères gastriques ou duodénaux par administration d'une composition pharmaceutique comprenant un oligosaccharide de la formule (I): NeuAc-.alpha.(2-3)-pGal-.beta.(1)-(-X-)¿m?-(-Y-)¿n?-)¿p?-Z. Dans cette formule générale (I), X représente une liaison chimique ou un groupe pouvant lier le p galactose soit au groupe de liaison Y, soit au support multivalent Z; où l'oxygène glycosidique C¿1? du galactose est remplaçable par N, S ou C; Y représente un groupe de liaison; Z représente un support multivalent; m est un entier valant 0 ou 1; n est un entier valant 0 ou 1; et p est un entier valant de 2 à 1000. L'invention concerne en outre un procédé traitant et/ou inhibant les ulcères gastriques et duodénaux par administration d'une composition pharmaceutique comprenant un oligosaccharide, de la formule (II): NeuAc-.alpha.(2-3)-pGal-.beta.(1)-A. Dans cette formule (II), A représente un groupe pouvant se lier au p galactose; l'oxygène glycosidique C¿1? du galactose étant remplaçable par N, S ou C.
CA002183329A 1994-03-02 1995-03-02 Procede de traitement et d'inhibition des ulceres gastriques et duodenaux Abandoned CA2183329A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20451594A 1994-03-02 1994-03-02
US204,515 1994-03-02

Publications (1)

Publication Number Publication Date
CA2183329A1 true CA2183329A1 (fr) 1995-09-08

Family

ID=22758224

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002183329A Abandoned CA2183329A1 (fr) 1994-03-02 1995-03-02 Procede de traitement et d'inhibition des ulceres gastriques et duodenaux

Country Status (5)

Country Link
EP (1) EP0749314A4 (fr)
JP (1) JP3179108B2 (fr)
AU (1) AU709149B2 (fr)
CA (1) CA2183329A1 (fr)
WO (1) WO1995023605A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
KR20000010732A (ko) * 1996-05-03 2000-02-25 스티븐 로쓰 시알릴올리고당의 비스무트염 및 이를 사용한위궤양 및 십이지장궤양 치료 및 억제 방법
EP1165097B1 (fr) * 1999-02-01 2007-05-02 Dermal Research Laboratories, Inc. Composition pharmaceutique d'hydrates de carbone complexes l'utilisation de celle-ci
SE9901007D0 (sv) * 1999-03-19 1999-03-19 Thomas Boren Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
NL2007931C2 (en) * 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
WO2020060260A1 (fr) * 2018-09-20 2020-03-26 가톨릭대학교 산학협력단 Composite polymère pour la reconnaissance de l'helicobacter pylori et composition pour la thérapie photodynamique la comprenant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
US5260280A (en) * 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
JPH0436294A (ja) * 1990-06-01 1992-02-06 Snow Brand Milk Prod Co Ltd 牛乳由来の新規なガングリオシド及びその製造法
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5254676A (en) * 1991-11-22 1993-10-19 E. I. Du Pont De Nemours And Company Oligosaccharide inhibitors for influenza virus
EP0630251A1 (fr) * 1992-03-19 1994-12-28 University Of British Columbia Procede et composition permettant de supprimer les effets secondaires de medicaments anti-inflammatoires
AU4055993A (en) * 1992-05-15 1993-12-13 University Of British Columbia, The N-acetyl glucosamine as gastroprotective agent
AU4993893A (en) * 1992-07-31 1994-03-03 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers

Also Published As

Publication number Publication date
EP0749314A4 (fr) 2002-09-18
AU1932395A (en) 1995-09-18
AU709149B2 (en) 1999-08-19
JP3179108B2 (ja) 2001-06-25
EP0749314A1 (fr) 1996-12-27
WO1995023605A1 (fr) 1995-09-08
JPH09509931A (ja) 1997-10-07

Similar Documents

Publication Publication Date Title
US5514660A (en) Method for treating and inhibiting gastric and duodenal ulcers
US6110897A (en) Antiinflammatory cell adhesion inhibitors
KR19990022658A (ko) 올리고사카라이드 화합물에 의한 박테리아 저해물질
MXPA96003403A (en) Treatment of diarrhea associated with antibioti
JP6265985B2 (ja) 多量体マンノシド類、その製造方法および医薬としての使用
NZ264517A (en) An antiulcer agent comprising fucoidan as adhesion inhibitor
WO1994003184A1 (fr) Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux
Simon Pharmaceutical oligosaccharides
CA2183329A1 (fr) Procede de traitement et d'inhibition des ulceres gastriques et duodenaux
US20160361423A1 (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection
CA2191960A1 (fr) Modulateurs de l'adherence des pneumocoques aux cellules pulmonaires et vasculaires et applications diagnostiques et therapeutiques
AU710576B2 (en) Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
WO1998026662A1 (fr) Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
WO1998026662A9 (fr) Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
PT655249E (pt) Moenomicina como medicamento para o tratamento de ulceras gastricas
JPH07502011A (ja) 免疫抑制性および寛容原性のオリゴ糖誘導体
MXPA98009158A (en) Salt of bismuto de sialiloligosacarido and a metodopara treat and inhibit gastric and duodenal ulceras with the mi
DE10138935A1 (de) Synthetische Verbindungen vom Nicht-Mucintyp oder ihre mit einem Träger konjugierten Verbindungen
EP1169044A1 (fr) Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne
US20020173483A1 (en) Chlamydia oligosaccharides
JP2004002239A (ja) ＴＮＦ−α産生抑制剤
WO1998004272A1 (fr) Oligosaccharides de chlamydiae
MXPA98001875A (en) Salts of bismuto of antibiotics of the lamoenomycin group, procedure for its preparation, its use and medicines containing such sa

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead